Cough
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- 4 industry developments reported.
- Q3 2027A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China Extension
- Q4 2027A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted Cough
- Q4 2028Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI
Clinical MilestonesViewHide
- 2026-06-16A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China ExtensionResults expected Q3 2027
- 2026-05-13A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted CoughResults expected Q4 2027
- 2026-02-13Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVIResults expected Q4 2028
- 2026-06-18A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)Completed
- 2025-10-03A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of Reconyl in Acute Cough TreatmentCompleted
Industry & MarketViewHide
- 2026-07-17GSK axes key cough drug candidate after phase 3 data end blockbuster hopesTrial news · Fierce Biotech
- 2026-09-15Cough hypersensitivity risk increases during heatwaves and can be reduced by inhalation of alkaline aerosols of endogenous ionsIndustry · Nature — Environmental Sciences
- 2026-09-15Short-term associations between air pollution and nocturnal cough frequencyIndustry · Nature — Climate Sciences
- 2026-07-17STAT+: The end for GSK’s chronic cough treatmentIndustry · STAT News
- 2026-09-15IndustryCough hypersensitivity risk increases during heatwaves and can be reduced by inhalation of alkaline aerosols of endogenous ionsIndustry · Nature — Environmental Sciences
- 2026-09-15IndustryShort-term associations between air pollution and nocturnal cough frequencyIndustry · Nature — Climate Sciences
- 2026-07-17IndustrySTAT+: The end for GSK’s chronic cough treatmentIndustry · STAT News
- 2026-07-17IndustryGSK axes key cough drug candidate after phase 3 data end blockbuster hopesTrial news · Fierce Biotech
- 2026-06-18ClinicalA Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)Completed
- 2026-06-16ClinicalA Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China ExtensionResults expected Q3 2027
- 2026-05-13ClinicalA Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted CoughResults expected Q4 2027
- 2026-02-13ClinicalMulticenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVIResults expected Q4 2028
- 2025-10-03ClinicalA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of Reconyl in Acute Cough TreatmentCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic coug… (2023)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Disease Outbreaks2
- Air Movements1
- Air Pollutants1
- Betacoronavirus1
- Coronavirus Infections1
- COVID-191
- Exhalation1
- Models, Theoretical1
Leading journals6
- Immunity, inflammation and disease1
- Indoor air1
- Journal of internal medicine1
- Military Medical Research1
- PloS one1
- Scientific reports1
Leading researchers8
- Adachi D1
- Ameeq M1
- Anfinrud P1
- Arbyn M1
- Asadi S1
- Ayers M1
- Barreda S1
- Bax A1
Affiliations (unnormalised)6
- Air Quality Research Center1
- Bristol Medical School1
- Center for Interventional Medicine1
- Center of Infectious Disease1
- Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging1
- Icahn School of Medicine at Mount Sinai1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Cough is a sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that helps clear the trachea, bronchi, and lungs of irritants and secretions, and helps prevent aspiration of foreign material into the airways.
The supplied grounding does not identify specific causes of cough as a disease entity. It only describes cough as a protective respiratory response and notes its occurrence in the context of COVID-19.
Cough involves inhalation followed by forceful expulsion of air through a partially closed glottis. The mechanism is a protective exhalation-based reflex that clears airway irritants and secretions and reduces aspiration risk.
The supplied grounding does not support a general treatment standard for cough. In the provided literature, cough is discussed mainly as a symptom in COVID-19 and as a contributor to respiratory droplet transmission, rather than as a condition with a defined modality-based treatment approach.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.